BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2977429)

  • 1. [Changes in plasma levels of androgens and SHBG in patients with polycystic ovary syndrome (PCOs) treated with oral contraceptives containing desogestrel].
    Negri P; D'Errico G; Minisci N; Tomasi A
    Minerva Ginecol; 1988 Dec; 40(12):699-707. PubMed ID: 2977429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHBG, testosterone, androstenedione, 17-OH-Progesterone plasma levels in PCO affected women treated with a triphasic oral contraceptive.
    Negri P; Agnello G; Borghesani F; Tomain L; Minisci N; D'Errico G; Cavallini AR
    Acta Eur Fertil; 1987; 18(6):375-80. PubMed ID: 3454501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
    Sobbrio GA; Granata A; D'Arrigo F; Arena D; Panacea A; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1990; 21(3):139-41. PubMed ID: 2149912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome.
    De Leo V; Di Sabatino A; Musacchio MC; Morgante G; Scolaro V; Cianci A; Petraglia F
    Contraception; 2010 Sep; 82(3):276-80. PubMed ID: 20705157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term treatment of hirsutism related to micropolycystic ovary syndrome with a combination type oral contraceptive containing desogestrel.
    Sobbrio GA; Granata A; D'Arrigo F; Arena D; Trimarchi F; Granese D; Pullè C
    Acta Eur Fertil; 1989; 20(1):35-7. PubMed ID: 2528880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a low-dose desogestrel-ethinylestradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome.
    Cullberg G; Hamberger L; Mattsson LA; Mobacken H; Samsioe G
    Acta Obstet Gynecol Scand; 1985; 64(3):195-202. PubMed ID: 3160211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the androgenicity of four low-dose, fixed-combination oral contraceptives.
    Coenen CM; Thomas CM; Borm GF; Rolland R
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():92-7. PubMed ID: 8574256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic studies on desogestrel administered alone and in combination with ethinylestradiol.
    Cullberg G
    Acta Obstet Gynecol Scand Suppl; 1985; 133():1-30. PubMed ID: 3161265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a combination of ethinylestradiol and desogestrel in adolescents with oligomenorrhea and ovarian hyperandrogenism.
    Nappi C; Farace MJ; Leone F; Minutolo M; Tommaselli AP; Montemagno U
    Eur J Obstet Gynecol Reprod Biol; 1987 Jul; 25(3):209-19. PubMed ID: 2956138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L; Dordoni D; Gastaldi C; Gastaldi A
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A
    Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Palatsi R; Hirvensalo E; Liukko P; Malmiharju T; Mattila L; Riihiluoma P; Ylöstalo P
    Acta Derm Venereol; 1984; 64(6):517-23. PubMed ID: 6084924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of desogestrel and ethinylestradiol combination in normal and hyperandrogenic young girls: speculations on contraception in adolescence.
    Venturoli S; Porcu E; Gammi L; Fabbri R; Paradisi R; Flamigni C; Patrono D; Capelli M; Paoletti C
    Acta Eur Fertil; 1988; 19(3):129-34. PubMed ID: 2976224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on acne of two oral contraceptives containing desogestrel and cyproterone acetate.
    Charoenvisal C; Thaipisuttikul Y; Pinjaroen S; Krisanapan O; Benjawang W; Koster A; Doesburg W
    Int J Fertil Menopausal Stud; 1996; 41(4):423-9. PubMed ID: 8894800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desogestrel in monophasic E/P combination: monitoring of endocrine parameters and evaluation of hemostatic function.
    Bruni V; Rosati D; Bucciantini S; Verni A; Abbate R; Costanzo M; Pinto S; Costanzo G
    Acta Eur Fertil; 1987; 18(4):277-80. PubMed ID: 2969168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
    Kuhnz W; Schütt B; Power J; Back DJ
    Arzneimittelforschung; 1992 Sep; 42(9):1139-41. PubMed ID: 1445482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
    Leelaphiwat S; Jongwutiwes T; Lertvikool S; Tabcharoen C; Sukprasert M; Rattanasiri S; Weerakiet S
    J Obstet Gynaecol Res; 2015 Mar; 41(3):402-10. PubMed ID: 25319761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
    Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
    Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.